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Purpose: Drug treatment can be effective in community-based settings, but drug users tend to underuse
these treatment options and instead seek services in emergency departments (EDs) and other acute care
settings. The goals of this study were to describe prevalence and correlates of drug-related ED visits.
Basic procedures: This study used data from the National Epidemiologic Survey on Alcohol and
Related Conditions, which is a nationally representative survey of 43 093 US residents.
Main findings: The overall prevalence of drug-related ED visits among lifetime drug users was 1.8%;
for those with a lifetime drug use disorder, 3.7%. Persons with heroin dependence and inhalant
dependence had the highest rates of ED visits, and marijuana dependence was associated with the lowest
rates. Multivariate analyses revealed that being socially connected (ie, marital status) was a protective
factor against ED visits, whereas psychopathology (ie, personality or mood disorders) was a risk factor.
Conclusions: Significant variability exists for risk of ED use for different types of drugs. These findings
can help inform where links between EDs with local treatment programs can be formed to provide
preventive care and injury-prevention interventions to reduce the risk of subsequent ED visits.
© 2010 Published by Elsevier Inc.Drug use and abuse is a major public health problem that
can lead to serious health consequences, criminal involve-
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lower quality of life [1-5]. Drug treatment can be effective in
community-based settings, but drug users tend to underuse
these treatment options and instead seek services in
emergency departments (EDs) and other acute care settings
[6-9]. These settings are often the most expensive and least
effective way of addressing drug problems. Research on
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problems often require treatment over the course of several
months [10]. Recent research also shows that drug-related
ED use is increasing [11], resulting in billions of dollars in
costs to the public health care system [12-17]. The costs are
even higher when other drug treatment services and criminal
justice expenditures are considered [18].1. Importance
Research on the burden of alcohol and associated ED and
acute care service use is well developed, but little is known
about drug-related burden and associations. Increasing this
body of research is necessary given evidence suggesting that
the consequences of drug use on ED and primary care service
settings may be greater than those of alcohol use alone
[17,19]. This research is needed to ensure that supportive
policies are implemented and funding delivered to treat these
chronic conditions in community-based settings [20]. This
research can also contribute to the development of effective
and efficient assessments and brief interventions appropriate
for ED and acute care settings [21]. Finally, identifying
repeat ED and acute care service users, and describing their
clinical and psychosocial profiles, can lead to targeted
approaches for treatment of persons who have the greatest
impact on the health care system [20]. Leading experts in
alcohol and drug treatment services recommend using
population-based surveys to understand the burden placed
by substance misuse on the general health care system and
characteristics of substance-related service users [19,21].
1.1. Goal of this investigation
The goal of this investigation was to gain a better
understanding of drug-related ED visits using nationally
representative data. Specifically, this study sought to
(1) describe sociodemographic patterns and correlates
of drug-related ED visits and (2) examine prevalence of
drug-related ED visits for different types of drug use and
drug use disorders.2. Methods
2.1. Subjects, sampling, and interviews
This study used data from the National Epidemiologic
Survey on Alcohol and Related Conditions (NESARC),
which is a nationally representative survey of 43 093
noninstitutionalized US residents 18 years and older [22].
The NESARC was based on a multistage sampling design,
oversampling young adults, Hispanics, and blacks to obtain
reliable statistical estimation in these subpopulations and to
ensure appropriate representation of racial/ethnic groups.The overall response rate was 81%. Data were weighted at
the individual and household levels and to adjust for
oversampling and nonresponse on select demographic
variables. Data were also adjusted to be representative of
the US population as assessed during the 2000 census.
In the administration of this survey, US Census Bureau
workers, trained by National Institute on Alcohol Abuse and
Alcoholism staff, administered the Alcohol Use Disorders
and Associated Disabilities Interview Schedule—
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) version (AUDADIS-IV). AUDA-
DIS-IV is a structured interview designed for administration
by trained lay interviewers. AUDADIS-IV assesses 10
DSM-IV (APA, 2000) substance use disorders and has
evidenced good-to-excellent reliability for the assessment of
substance use disorders [23,24]. Descriptions of the
NESARC survey, sampling protocol, and related publica-
tions are described in detail in prior studies [22-24]. These
data are publicly available, and all identifying information
have been removed. This secondary data analysis met
exemption from institutional review board approval.
2.2. Measurement
2.2.1. Drug use and drug use disorders
In this study, drug use refers to any lifetime history of any
nonnicotine drug for purposes of getting high, including
amphetamines, sedatives, tranquilizers, opioids, cannabis,
cocaine and crack, hallucinogen, inhalants, heroin, and other
drugs. Drug use disorder refers to meeting DSM-IV criteria
for either drug abuse or drug dependence for any of the
aforementioned drug types.
2.2.2. Drug treatment and ED service use
Participants were asked to reply yes or no to the questions:
“Have you ever gone anywhere or seen anyone for a reason
that was related in any way to your use of medicines or drugs
—a physician, counselor, Narcotics Anonymous, or any
other community agency or professional?” Participants who
endorsed this question were then asked whether they used
any of 14 different treatment services, such as 12-step,
clergy, outpatient, and inpatient (the full set of services are
summarized in Table 3). Use of ED services was based on
the question, “In your entire life, did you ever go to an
emergency room for any reason related to your drug use?”
(yes/no).
2.2.3. Sociodemographic variables
Several sociodemographic and clinical variables were
assessed in this study: racial/ethnic groups including whites
(non-Hispanic), blacks, and Hispanics, sex (male, female),
living area (urban, rural), marital status (married, separated,
never married), annual personal income (in dollars), age (in
years), and employment status (employed, unemployed).
Insurance status referred to current private or public
insurance at the time of interviewing (eg, Medicare,
3Drug-related ED visits
ARTICLE IN PRESSMedicaid, CHAMPUS, CHAMPVA, VA, or other military
health care). Data regarding insurance status at time of
diagnosis or when treatment was sought are not available in
the NESARC data set.
2.2.4. Clinical variables
Five clinical variables were included in this study:
lifetime history of a DSM-IV alcohol use disorder (ie,
abuse or dependence), lifetime history of an anxiety disorder
(ie, social phobia, panic disorder with or without agorapho-
bia, and generalized anxiety disorder), and lifetime history of
a mood disorder (ie, major depression, bipolar disorder,
dysthymia, cyclothymia), personality disorder (ie, antisocial,
avoidant, dependent, obsessive-compulsive, paranoid, schiz-
oid, and histrionic), and polydrug use disorder (ie, having a
lifetime history of N3 nonnicotine or noncaffeine DSM-IV
drug use disorders). Note that this definition of polydrug use
disorder differs from that of polysubstance-related disorder
as defined in DSM-IV (p. 293). Last, it is necessary to note
that when assessed for anxiety disorder–related symptoms,
participants were not assessed for posttraumatic stress
disorder–related symptoms.
2.2.5. Analytic plan
Analyses were computed using SUDAAN Version 9.0
(Research Triangle Institute, Research Triangle Park, NC)
[25]. This system implements a Taylor series linearization to
adjust standard errors of estimates for complex surveyTable 1 Sociodemographic composition of subgroups defined by their
IV drug use disorder
Any drug use






Less than high school 17.4 11.1
High school/GED 34.3 25.9




Never married 31.0 26.6
Household income 9.
$0-$19 999 42.0 20.3
$20 000-$34 999 23.0 17.9
$35 000-$69 999 20.2 32.5





Sex: male 60.7 56.6 0.sampling design effects including clustered data. χ2 tests
were used to make bivariate comparisons of study variables.
Multivariate logistic regression analyses were used to
examine service use and barriers among racial and ethnic
groups, while adjusting for other sociodemographic and
clinical variables. These covariates were selected based on
theoretical plausibility and prior empirical findings.3. Results
3.1. Characteristics of drug-related ED service users
Approximately 21.2% of persons in the NESARC survey
reported a lifetime history of drug use, and 9.4% of the
sample met lifetime criteria for a drug use disorder (abuse or
dependence; excludes alcohol and nicotine). χ2 tests were
used to identify associations between drug-related ED visits
and other sociodemographic and clinical variables. Analyses
were conducted separately for persons with lifetime drug use
and a lifetime drug use disorder. The overall prevalence of
drug-related ED visits among lifetime drug users was 1.8%;
for those with a lifetime drug use disorder, 3.7%.
As summarized in Table 1, among persons with lifetime
drug use, the prevalence of having lower educational
attainment, being not currently married, and having lower
income was higher among those with at least one drug-ED use among persons with any psychoactive drug use or a DSM-
Any drug use disorder
2 (df), P ED use (%) No ED use (%) χ2 (df), P





















79 (1), .38 61.4 64.2 0.39 (1), .53
Table 3 Drug-related service use among individuals with and







NA/AA/12-step 67.0 59.2 4.5, .04
Family/social services 36.0 17.3 11.1, .001
Detoxification 56.3 33.2 15.7, b.001
Inpatient 59.2 22.5 40.9, b.001
Outpatient/partial
hospitalization
49.4 32.2 10.5, .002
Rehabilitation 61.7 47.6 7.1, .01
Methadone maintenance 10.6 3.6 6.7, .02
Halfway house 24.5 8.1 15.4, b.001
Crisis center 15.5 3.5 12.6, b.001
Employee assistance
program
15.2 7.8 3.3, .08
Clergy/priest/rabbi 29.3 17.7 6.0, .02
Private professional 68.3 51.1 9.0, .004
Other 23.3 8.8 13.3, b.001
NA, narcotics anonymous; AA, alcoholics anonymous.
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Among persons with a lifetime drug use disorder, the
prevalence of having at being currently not married and
having a low income was higher among those who had at
least one drug-related ED visit than those who had not.
3.2. ED use by drug type
To examine how the percentage of persons with a drug-
related ED visit differs for each drug, the weighted
percentage of users who had a drug-related ED visit was
estimated separately for each type of drug examined. These
percentages, as well as unweighted sample sizes are
presented in Table 2. Although heroin was the least
commonly used drug, persons who had ever used heroin
had a high percentage of drug-related ED visits (18.54%; SE,
3.66). In contrast, marijuana was by far the most commonly
used drug, but individuals who used marijuana had a low
prevalence of drug-related ED visits (1.71%; SE, 0.16). For
all remaining drug types, the prevalence of drug-related ED
visit among people who had used that drug ranged between
3.92% and 6.33%.
Among persons with a drug use disorder, the results were
similar to those of persons who had ever used a drug.
Individuals with a heroin use disorder had the highest
prevalence of drug-related ED use (26.83%; SE, 5.17), and
individuals with a marijuana use disorder had the lowest
(3.05%; SE, .34). Persons with other drug use disorders had a
prevalence of ED use between 7.53% and 16.02%,Table 2 Prevalence of drug-related ED visits by type of drug
use and lifetime drug use disorder
Drug type N Drug-related ED
visit % (95% CI)
Amphetamine use 1750 4.5 (3.6-5.7)
Amphetamine use disorder 765 7.9 (6.1-10.3)
Sedative use 1609 5.3 (4.2-6.8)
Sedative disorder 402 11.3 (8.4-14.9)
Tranquilizer use 1301 6.3 (4.9-8.1)
Tranquilizer use disorder 372 13.1 (10.0-16.9)
Opioid use 1815 5.2 (4.2-6.6)
Opioid use disorder 521 10.5 (7.9-13.8)
Cannabis use 8172 1.7 (1.4-2.1)
Cannabis use disorder 3297 3.1 (2.4-3.8)
Cocaine/crack use 2528 4.2 (3.3-5.2)
Cocaine/crack use disorder 1159 7.6 (6.0-9.6)
Hallucinogen use 2176 3.9 (3.1-4.9)
Hallucinogen use disorder 623 7.5 (5.7-9.8)
Inhalant use 664 6.2 (4.4-8.8)
Inhalant use disorder 138 16.0 (10.4-23.9)
Heroin use 150 18.5 (12.3-26.9)
Heroin use disorder 104 26.8 (17.8-38.3)
Other drug use 87 12.3 (6.5-22.0)
Other drug use disorder 39 14.5 (5.9-31.3)
All drug use disorders based on DSM-IV criteria.depending on the drug. Although not formally tested, ED
visits appeared to be more common for each drug examined
among those who met criteria for a disorder than the larger
group of persons who reported lifetime use (with or without
a disorder).
3.3. Differences in service use
The prevalence of other drug-related service use among
individuals who have and have not had a drug-related ED
visit was also examined among individuals with a drug use
disorder (Table 3). Across all types of services assessed,
individuals who have had a drug-related ED visit were more
likely to report also having used other services. The most
frequently used services among individuals who have had
an ED visit were “narcotics/alcoholics anonymous or any
12-step meeting” (67.0%) and private professionals,
including psychiatrics, psychologists, social workers, and
others (68.3%).
3.4. Factors associated with one or more
drug-related ED visits
Logistic regression was used to further examine the
relationship between drug-related ED visits and several
demographic and mental health variables, as well as number
of lifetime drug use disorders, alcohol use disorder, and
service use, among individuals with a drug use disorder.
Table 4 reports the odds ratio and 95% confidence interval
for each independent variable used in the multivariate
regression analysis. The odds of having a drug-related ED
visit for persons with a drug use disorder who had been
widowed, divorced, or separated was 1.8 times the odds
Table 4 Multivariate association between service use and
drug-related ED visits among persons with a drug use disorder
Odds ratio 95% CI
Sex: male 0.98 0.60-1.61
Education (less than high school is reference)
High school/GED 0.96 0.50-1.86
Some college or greater 0.91 0.46-1.79
Marital status (never married is reference)
Married 0.80 0.42-1.52
Widowed/divorced/separated 1.81 1.04-3.15
Household income (≥$70 000 is reference)
$0-$19 999 1.06 0.47-2.42
$20 000-$34 999 1.10 0.50-2.44
$35 000-$69 999 0.57 0.25-1.27
No. of drugs disorders (1 is reference)
2 1.00 0.34-2.91
≥3 2.21 0.86-5.69
Alcohol use disorder 0.54 0.25-1.18
Mood disorder 1.79 1.07-2.00
Any personality disorder 1.60 1.03-2.48
Any service use 2.12 0.56-8.01
Values in bold are statistically significant based on an odds ratio that
does not bound 1.0.
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95% confidence interval [CI], 1.04-3.15). Having a mood
disorder increased the likelihood of a drug-related ED visit
by 1.79 times among persons with a drug use disorder (95%
CI, 1.07-3.00). Similarly, the odds of having a drug-related
ED visit for persons with a personality disorder were 1.6
times the odds compared to persons without a personality
disorder (95% CI, 1.03-2.48). Age, sex, race, education,
number of drug use disorders, alcohol use disorder, and
anxiety disorder were not significant correlates of having a
drug-related ED visit.4. Discussion
To date, this is the first study that has used nationally
representative data to examine patterns and correlates of
drug-related ED visits. This study overcomes challenges of
limited generalizability and regional variability that are
common to clinic-based surveys. A particularly important
feature of this study is the focus on drug-related ED visits
across different classes of drugs, which enables a better
understanding of the service consequences of different drug
types. This is particularly important for tailoring interven-
tions and targeting services.
The overall prevalence of drug-related ED use among
persons with lifetime drug use and those with a lifetime
drug use disorder was low. However, disaggregating the
prevalence by types of drugs of abuse revealed that the
prevalence is driven downward by the high prevalence ofmarijuana use and disorders but low ED use for that
particular substance. However, drugs such as heroin,
inhalants, and “other drugs” were less commonly used but
associated with significantly higher rates of ED use for
individuals who use marijuana. Thus, the low overall rate can
be attributed to the large number of marijuana users and
those with a marijuana use disorder and the relatively low
risk of ED visits for this drug. This finding indicates that ED
clinicians see a disproportionate number of individuals who
use substances such as heroin, inhalants, and “other drugs”
and may be uniquely well positioned to provide drug-related
interventions and make referrals to drug treatment specifi-
cally for these substances.
Interestingly, the prevalence of ED use among lifetime
users of heroin and “other drugs” (18.5% and 12.3%,
respectively) approached the same rate of ED use among
those with a parallel lifetime drug use disorder (26.8% and
14.5%). For other drugs, the prevalence of ED use twice as
prevalent among persons with substance use disorder
compared to persons who reported lifetime use only. This
demonstrates the substantial consequences of heroin use and
abuse on the health care system, underscoring the need for
intervention among those with and without a heroin use
disorder. The types of drugs included in the “other drug use”
category were not available in the data set. However, results
suggest the importance of doing a wide range of assessments
for specific types of drug use as opposed to only major
classes of drugs.
The high prevalence of ED use among persons with an
inhalant use disorder is also particularly notable. Inhalant
use disorders were associated with a high prevalence of ED
visits, second only to heroin. Inhalants are among the most
common and dangerous of all types of psychoactive
substances but the least studied [26], and few studies
exist on patterns of service use among this group. These
findings indicate the need for future work on inhalant use
disorders and emergency service use. Although these
findings further confirm the significant consequences of
inhalant use and the need for prevention, it is also important
to consider that inhalants are an indicator of multiple
psychiatric and substance use comorbidities [27,28], which
could be the underlying factors for ED use. The ED
facilities may be particularly well positioned to reach out to
inhalant users who are otherwise missed through current
outreach efforts and to engage in research with this under-
studied population.
Some psychosocial and clinical factors also emerged in
the multivariate analysis. Specifically, being socially
connected (ie, marital status) was a protective factor against
ED visits, whereas psychopathology (ie, personality or mood
disorder) was a risk factor. These findings are consistent with
other research on drug use disorders and their functional
impacts. Future research should consider the direction of
effects and effect sizes in disaggregated analyses. It was
beyond the scope of the current study to examine the
different multivariate associations due to low cell counts and
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provides the basic framework for a disaggregated approach
to facilitate analysis of specific drug types with adequate
sample sizes.
Regarding service use, persons who reported an ED use
were likely to have also reported lifetime use of other
services. It is possible that referrals for other services were
received from the ED. However, the limitations of the
existing data do not allow us to determine pathways or
temporal ordering of service use. Other services used could
be a response to the ED treatment (eg, inpatient treatment) or
part of the pathway (eg, crisis center). However, these data
can be used to help inform where links between EDs with
local treatment programs can be formed to provide
preventive care and injury-prevention interventions to reduce
the risk of subsequent ED visits.
4.1. Study limitations
The findings should be considered in the context of the
study limitations. For example, data are not available on the
number of drug-related ED visits, which is necessary for
understanding the differential risks of different types of drug
use. Although this study considered the role of other drug use
disorders regarding ED visits, the study could not effectively
address possible complex interactions between different
types of drugs and resultant ED visits. The specific reasons
for ED visits were not available in this data set. Although the
survey clearly queried respondents about specific drug-
related ED visits, the nature of the injuries and type of
medical attention sought would be particularly informative.
Finally, the NESARC was not designed to provide
information on whether an intervention provided in the ED
was effective in reducing drug use, accessing treatment
services, or preventing future ED use.Acknowledgments
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